Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service – results from the prospective, multi-center, observational cohort study thrombEVAL

2,771 patients receiving oral anticoagulation therapy (predominantly phenprocoumon) for indications including atrial fibrillation, venous thromboembolism, and prosthetic heart valves. The cohort includes 2,011 patients in regular medical care (median age 73, 62.2% male) and 760 patients in a telemedicine-based coagulation service (median age 73, 52.0% male).

Management of oral anticoagulation therapy (phenprocoumon) via a specialized, telemedicine-based coagulation service utilizing electronic patient files, computer-assisted dosing algorithms, and monitoring by trained nurses and physicians.

Regular medical care for oral anticoagulation management, with prescription and dosing independently performed by general practitioners and ambulatory specialists.

Time in therapeutic range (TTR) calculated by the linear interpolation method.surrogate